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Objective. To assess the evolution of joint mobility over a period of 15 years in type 1 diabetic patients and healthy controls
and to determine whether microalbuminuria is associated with a different evolution of joint mobility. Methods. Joint mobility
of hand and wrist was determined in 63 patients with type 1 diabetes and 63 healthy subjects. Fifteen years later, 37 (58.7%)
diabetic patients and 16 (25.4%) healthy subjects were studied again. Joint mobility was assessed with the Prayer sign and by
measuring the angle of maximal flexion of the fifth and third metacarpophalangeal (MCP) joints and wrist. Patients with
diabetes were visited 2–4 times every year with regular assessment of glycated hemoglobin (HbA1c), urinary albumin excretion
(UAE), and ophthalmoscopy. Results. Fifteen years after the initial exam, diabetic patients showed reduced flexion of the fifth
MCP joint (82.6± 5.8 versus 76.0± 6.4 degrees, p < 0 001) and wrist (75.9± 8.1 versus 73.2± 7.4 degrees, p = 0 015) compared to
baseline examination. Joint mobility did not change significantly in healthy subjects. Patients with microalbuminuria showed
greater reduction in hand joint mobility than diabetic patients with normal UAE or than healthy subjects (p < 0 001).
Conclusions. In type 1 diabetic patients, the severity of LJM progresses with time, and the progression is enhanced in patients
with microalbuminuria.
1. Introduction
Limited joint mobility (LJM), a nonpainful contracture of
finger joints, is the most common hand abnormality in
diabetes, but it has received little attention in clinical research
and care [1–3]. LJM usually begins at the fifth interphalan-
geal joints and extends radially, affecting other interphalan-
geal and metacarpophalangeal joints. Long-term glycemic
control influences the onset of LJM, and the incidence of
LJM is greater in patients with a poor metabolic control
[4, 5]. Although some studies have shown that improvement
in standards of glycemic control and diabetes care has
reduced the prevalence of LJM [6, 7], the Diabetes Control
and Complications Trial (DCCT) could not show a consis-
tent association between intensive insulin therapy and the
elements of cheiroarthropathy [5]. The prevalence of LJM
has been reported to increase with diabetes duration [5, 8].
However, age may be a confounding factor in the increased
prevalence of LJM with longer diabetes duration since joint
mobility deteriorates with aging [9, 10].
It has been shown that in elderly patients, diabetes
adds a negative effect on LJM [9]. However, an association
between LJM with diabetes duration as age increases has
not been established [9]. Moreover, the few prospective
studies that have determined joint mobility in diabetic
subjects have not included a control group of healthy subjects
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[11–13]. Thus, it is not well established whether the evolution
of LJM with aging is different in patients with diabetes and in
the general population.
Cross-sectional studies have reported an association
between LJM and microvascular complications [5, 7, 14–
19], and the presence of LJM is considered a useful clinical
tool to identify patients at increased risk for developing dia-
betic microvascular complications. However, prospective
studies have yielded controversial results. In adults, the role
of LJM in the prediction of microvascular diabetic complica-
tions has not been confirmed [11, 12], whereas in children,
LJM is associated with an increased risk of microalbuminuria
[13]. In a previous study [14], we found that hand joint
mobility was limited in type 1 diabetic patients compared
with control subjects and that LJM was associated with
microalbuminuria. In the current follow-up study, per-
formed 15 years later after the initial evaluation, we aimed
to determine whether the evolution of joint mobility is differ-
ent in diabetic and nondiabetic subjects and whether it is
modified in the presence of albuminuria.
2. Methods
2.1. Subjects. In a previous study, we measured joint mobility
in 63 patients with type 1 diabetes recruited from the outpa-
tient clinic and in 63 age- and sex-matched healthy subjects
[14]. The inclusion/exclusion criteria were described in the
baseline study [14]. For the current study, the cohorts of dia-
betic patients and healthy subjects were contacted 15 years
later and invited to participate in this follow-up study.
Thirty-seven type 1 diabetic patients (58.7% of the initial
cohort) and 16 healthy subjects (25.4% of the initial cohort)
were accepted to participate and were included in the study.
The clinical characteristics of patients and control subjects
included in the follow-up were not significantly different
from those of the initial study.
2.2. Joint Mobility. Joint mobility was assessed by the same
rheumatologist (AR) that performed the initial assessment
and using the same methodology. He was unaware of the
metabolic control of patients, presence of diabetic complica-
tions, and individual values of the baseline joint mobility
assessment. Joint mobility was determined qualitatively with
the Prayer sign and quantitatively by measuring the maximal
flexion of the fifth and third metacarpophalangeal (5MCP,
3MCP) joints and wrist, as previously described [14]. The
maximal extension of the 5MCP and 3MCP joints was not
recorded since the values, in both diabetic and control sub-
jects, were inconsistent with those of baseline examination.
In brief, the Prayer sign was defined as positive when subjects
were unable to oppose palmar surfaces at any interphalangeal
or MCP joint. To measure the angle of active maximal flexion
of the fifth MCP joint, the fourth finger was fixed on a flat
surface and the subject was asked to actively perform the flex-
ion of the fifth finger at the level of the MCP joint. The angle
of maximal flexion was measured with a goniometer and
expressed in degrees using the zero method. To measure
the mobility of the third MCP joint, the second finger was
fixed. The arm and forearm were fixed in complete extension
to measure the angles of active maximal flexion and exten-
sion of the wrist. Both hands were evaluated in all subjects,
and the mean value between left and right measurements
was used for statistical calculations.
2.3. Metabolic Control and Microvascular Complications.
Medical records of the 15-year follow-up period were
reviewed. Five years after the baseline study, the method
to evaluate glycated hemoglobin was changed from HbA1
to the more specific HbA1c. Therefore, the metabolic control
of the follow-up period was calculated as the mean HbA1c
value of the final 10 years. Diabetic retinopathy was assessed
by direct ophthalmoscopy through dilated pupils. Urinary
albumin excretion (UAE) was determined in 24 hour sterile
urine. Albuminuria was defined as UAE greater than
30mg/24 h in two consecutive samples or in two of three
consecutive samples.
2.4. Statistical Analysis. Data were analysed using SPSS
15.0. Nonparametric tests Wilcoxon and Kruskal-Wallis
were used to compare continuous data between groups.
Kruskal-Wallis test was used to analyse differences in flexion
among control group, diabetic patients with normoalbumi-
nuria, and diabetic patients with microalbuminuria. Post
hoc analysis between two groups was performed with the
Wilcoxon test. Fisher exact test was used to compare cat-
egorical data between groups. The relationship between
continuous variables was assessed with Pearson’s correlation
coefficient. A p value <0.05 (two-tailed) was considered to
be significant.
3. Results
Clinical characteristics of diabetic patients at baseline and at
follow-up are shown in Table 1. Nondiabetic control subjects
Table 1: Clinical characteristics of diabetic patients (n = 37).
Baseline Follow-up
Age (years) 27.4 (12.5) 42.9 (12.3)
Female sex 19 (51.4) 19 (51.4)
Age at diabetes diagnosis (years) 19.8 (10.6) 19.8 (10.6)
Duration of diabetes (years) 7.7 (6.1) 22.6 (5.9)
BMI (kg/m2) 23.0 (3.0) 26.6 (4.0)
Systolic blood pressure (mmHg) 118.8 (14.6) 126.6 (19.5)
Diastolic blood pressure (mmHg) 71.1 (9.1) 72.1 (10.9)
HbA1 (%) 11.2 (1.7)
HbA1c (%) 8.1 (1.5)
a
Insulin dose (U/kg) 0.75 (0.18) 0.83 (0.17)
Smoking 5 (13.5) 8 (21.6)
Hypertension 6 (16.2) 9 (24.3)
Dyslipidemia 2 (5.4) 8 (21.6)
Retinopathy 13 (35.1) 18 (48.6)
Microalbuminuria 7 (18.9) 16 (43.2)b
Values are mean (SD) or number of patients (%). BMI: body mass index;
amean HbA1c values of the last 10 years of follow-up; btwo patients
showed macroalbuminuria at the end of follow-up.
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had a similar sex distribution (43.8% male patients) than dia-
betic patients but were slightly older (33.8± 10.9 versus
27.4± 12.5 years at baseline). Diabetic patients showed LJM
both at baseline and at follow-up compared with control sub-
jects (Table 2). Joint mobility deteriorated with time in dia-
betic patients that showed reduced flexion of 5MCP joint
and wrist at the end of follow-up compared to baseline
(Table 2). In contrast, no significant differences were detected
between baseline and follow-up in control healthy subjects.
The prevalence of Prayer sign was the same at baseline and
at follow-up examination and in the range of what has been
described in diabetic and in nondiabetic subjects [20, 21].
Patients with albuminuria showed greater reductions
in joint mobility after 15 years of follow-up than diabetic
patients with normal UAE or than healthy subjects
(Figure 1). In contrast, the presence of retinopathy was not
associated with greater reductions in joint mobility. Changes
in joint mobility were not associated with age, smoking,
hypertension, dyslipidemia, and duration of diabetes or
mean HbA1c levels. There were gender differences in the
reduction in wrist joint mobility, with a greater reduction
in male patients (males: −7.1± 7.2 versus females 0.8± 7.0,
p = 0 005). There were no significant differences in HbA1c
levels between patients with or without a Prayer positive sign.
4. Discussion
In this study, we show that, over a period of 15 years,
joint mobility deteriorated significantly in patients with
type 1 diabetes but not in healthy control subjects. Moreover,
diabetic patients with albuminuria showed a more severe
deterioration of joint mobility than those with normal UAE
or than control nondiabetic subjects. The changes of joint
mobility did not correlate with age, duration of diabetes, or
metabolic control and were not modified by the presence of
diabetic retinopathy.
To the best of our knowledge, this is the first study
prospectively comparing the evolution of joint mobility in
diabetic patients and nondiabetic subjects. The high preva-
lence of LJM in type 1 diabetes is well established [5], but lon-
gitudinal studies of joint mobility are scarce, and it is not
known whether the evolution is different in diabetic patients
and the general population. The presence of a control group
of nondiabetic subjects with similar age is essential for this
Table 2: Joint mobility in diabetic patients and healthy control subjects.
Joint mobility (degrees)
Patients with diabetes (n = 37) Control group (n = 16)
Baseline Follow-up Baseline Follow-up
Fifth metacarpophalangeal flexion 82.6 (5.8)†† 76.0 (6.4)∗∗ 86.0 (6.5) 85.8 (6.7)
Third metacarpophalangeal flexion 86.1 (3.8)∗ 85.2 (4.4) 89.8 (5.8) 88.0 (5.8)
Wrist flexion 75.9 (8.1)† 73.2 (7.4)∗ 76.3 (8.5) 76.5 (9.2)
Positive Prayer sign, n (%) 18 (48.6)∗ 18 (48.6)∗ 2 (12.5) 2 (12.5)
Values are mean (SD), except for Prayer sign (number and percentage) ∗p < 0 05, ∗∗p < 0 01 between patients and controls at each time point (Wilcoxon test for




























Figure 1: Change in hand joint flexion in diabetic patients (DM) with (n = 16) and without (n = 21) albuminuria and in healthy subjects
(n = 16) over 15 years. DM: diabetes mellitus; MCP: metacarpophalangeal. Error bars represent ±1 SE. ∗p < 0 001 between groups
(Kruskal-Wallis comparison). Post hoc between-group comparisons: control group versus diabetic patients without microalbuminuria,
p = 0 001; control group versus diabetic patients with microalbuminuria, p < 0 001; diabetic patients without microalbuminuria versus
diabetic patients with microalbuminuria p = 0 059.
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analysis, since age is associated with LJM [9]. In our initial
study [14], we found that joint mobility was reduced in
patients with type 1 diabetes compared with healthy controls.
We now show that 15 years later, joint mobility deteriorated
significantly in diabetic patients but did not change signifi-
cantly in control subjects, indicating that the progression of
limited joint mobility was specifically associated with the
presence of diabetes and was not due to aging.
Type 1 diabetic patients with albuminuria showed a
higher reduction in joint mobility after 15 years of follow-
up compared with diabetic subjects with normal UAE and
with control healthy subjects. In our initial cross-sectional
study, we found that LJM was associated with microalbu-
minuria [14], an observation that has been subsequently
confirmed by Amin et al. in a large longitudinal study [13].
We have now found that the presence of albuminuria is asso-
ciated with a more severe progression of LJM. A plausible
biological link between microalbuminuria and LMJ has been
proposed based on a common role of advanced glycation end
products in the development of LJM and diabetic compli-
cations including albuminuria [20–22]. However, other pro-
spective studies have failed to show a relationship between
microalbuminuria and LJM [11, 12]. Differences in the char-
acteristics of diabetic patients and in the duration of follow-
up may account for the discrepancy in the results. The
shorter follow-up period of previous studies may have been
insufficient to detect the association between microalbumi-
nuria and poor evolution of LJM.
Our study has some limitations. First, the sample size was
reduced from our initial study. Dropout rates may be
accounted by the difficulty in contacting the subjects after
this long follow-up period of 15 years and in particular the
control subjects. Nevertheless, diabetic and control groups
remained well matched in age and sex, and more than half
of the initial diabetic population participated in the follow-
up evaluation. Second, the extension mobility of the joints
could not be evaluated. Extension of the 5MCP and 3MCP
was already significantly reduced in diabetic subjects at base-
line, and we may speculate that the follow-up extension
measurements would have shown similar evolution than
the joint flexion. Third, we focused on the diabetic microvas-
cular complications that had been analysed in the baseline
study, retinopathy, and in particular albuminuria, and we
did not assess diabetic neuropathy. Reduced joint mobility
in the hand has been associated with a decline in mobility
in the ankle and is considered a risk factor for food ulcera-
tion in diabetic patients [21, 23]. However, diabetic neurop-
athy has not been consistently related to LJM [24]. Finally,
the evaluation was not fully blinded regarding the presence
of diabetes.
In summary, the present study shows the progressive
character of LJM in type 1 diabetic patients and underscores
the relationship between albuminuria and LJM. Periodic eval-
uation of joint mobility should be considered in patients with
type 1 diabetes, particularly when albuminuria is present.
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